Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 12.4% from a year ago
Property, plant & equipment (net) stood at $1.12M at the end of Q1 FY2026, down 12.4% from a year earlier and down 19.5% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.
Context
- Property, plant & equipment (net) amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -12.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 1.39M USD
- Year-over-year change
- +16.7%
- 3-year CAGR
- -8.3%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.39M | +16.7% |
| FY2024 | 2024-12-31 | 1.19M | +17.3% |
| FY2023 | 2023-12-31 | 1.01M | -43.7% |
| FY2022 | 2022-12-31 | 1.8M | — |
Property, Plant & Equipment (Net) vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 property, plant & equipment (net) of $1.12M is the 6th highest of the 8 companies compared; the peer median is $1.58M.
- Its year-over-year change of -12.4% is the 3rd highest of 7, against a peer median of -13.7%.
- Property, plant & equipment (net) amounts to 0.1% of total assets for ZBIO, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $24.87M | -12.8% | -10.5% | 9.5% | |
| Mar 2026 | $5.83M | -14.6% | -12.8% | 9.1% | |
| Mar 2026 | $2.89M | +206.5% | — | 1.5% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.58M | -27.7% | +121.4% | 0.5% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $1.17M | — | — | 0.4% |
| Mar 2026 | $1.12M | -12.4% | -8.3% | 0.1% | |
| Dec 2025 | $499K | +166.8% | +8.7% | 4.3% | |
| Sep 2026 | $262K | -58.5% | -30.1% | 0.0% | |
| Peer median (excluding ZBIO) | $1.58M | -13.7% | -10.5% | 1.5% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.